Subject Matter Expert Opinion

By David Richardson, Research Team Leader The Office of the Inspector General at Health and Human Services (OIG) has been highly focused recently on tracking and publicizing pharmaceutical companies' payments to thought leader physicians and clinical...

By Casey Ferrell, Senior Research Analyst In sports, payroll tends to have a big impact on the quality of a roster. Though it doesn't always equate to Stanley Cups or World Series rings, the rule is pretty simple: more money equals better players equals...

By Jeremy Spivey, Senior Research Analyst Advertising Age reports that Purdue Pharma is planning a major DTC ad campaign for its new product, Intermezzo. Although Intermezzo is based on the same active ingredient molecule as Ambien, a sublingual administration...

By Elio Evangelista, Director of Research The United States is still waiting for the Centers for Medicare and Medicaid Services (CMS) to issue its final ruling on how it will implement the disclosure rules outlined in the Physician Payments Sunshine...

By Eric Bolesh, Director of Research When we spoke with teams to complete our recent examination of companion diagnostics (CDx) development, we heard a lot about the difficulties of the partnering process. It’s a difficult road for all parties, as choosing...

By Michelle Vitko, Senior Research Analyst In an earlier blog post, I discussed the cost of patient non-adherence -- poorer health outcomes for patients and billions of dollars in lost product revenue. Low adherence rates have been a problem for a...

By Jeremy Spivey, Senior Research Analyst In an effort to expand Chinese citizens' access to certain high-volume pharmaceutical products, the Chinese government has committed to expanding a price-squeezing tendering system to the entire country. The...

Cutting Edge Information's new customizable "MSL Data Suite" combines the company's experience in researching medical science liaison performance and MSL program management with our team's strength in providing Life Science companies with benchmarking data, analysis...

By Ryan McGuire, Senior Research Analyst Pharmaceutical companies are growing more strategic in their investigator initiated trial (IIT) selection. As Research and Development organizations have sharpened their focus on mission-critical pre-approval...

By Elio Evangelista, Director of Research The promise of adaptive clinical trials leading to significant cost savings is attractive, and many drug companies have already put the strategy into practice. But most times, companies implement adaptive clinical...